PROM1 and cancer: Recruitment of CD133+ pro-angiogenic cells in cancer has been considered to play an important role in resistance to vascular growth factor (VEGF) neutralizing antibody such as bevacizumab, possibly due to failure to inhibit their differentiation into endothelial cell types [54].